Metsera’s (NASDAQ:MTSR – Get Free Report) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total size of ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze ...

This acquisition was part of the company’s underwritten offering of 35.74 ... is a stock that recently went public, analyst coverage is, so far, limited. Metsera is also one of the 10 stocks ...

The Company has granted the Underwriters an option to purchase up to 581,250 additional Ordinary Shares within 45 days of the closing of the Offering at the public offering price, less underwriting ...

NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.

KIRKLAND, Wash., March 05, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (“Kestra”), a wearable medical device and digital healthcare company, today announced the pricing of its upsized ...

Kestra Medical Technologies, Ltd., a company specializing in wearable medical devices and digital healthcare, announced the pricing of its initial public offering (IPO) of 11,882,352 common shares ...

Kestra Medical Technologies (NASDAQ:KMTS) stock debuts on Nasdaq with a 33% IPO jump. Learn about their growth, cardiac ...